Name the lipid measure that changed
NIH ODS identifies triglyceride lowering as an effect of long-chain omega-3 supplementation. A triglyceride result does not, by itself, report what happened to LDL cholesterol, HDL cholesterol or overall cardiovascular risk. [1]
The formulation and population also matter. Results from a specific prescription intervention should not be assigned to every retail oil product. [1]
A biomarker is not the same as a clinical event
ODS describes variation in cardiovascular outcome evidence. A favorable change in one laboratory measure does not automatically establish fewer heart attacks or strokes in every population. [1]
Discuss the intended lipid target and prescribed plan with the clinician. The relevant question is not simply whether a product contains fish oil, but which problem is being treated and what evidence matches it. [1]
Keep separate columns for separate outcomes
Imagine a study reports lower triglycerides but does not demonstrate fewer events. A summary should retain the triglyceride finding without adding an unmeasured clinical benefit.
| Detail | Interpretation |
|---|---|
| Triglycerides | One lipid endpoint |
| LDL cholesterol | Different measurement |
| Cardiovascular events | Patient-important outcome |
Sources for this article
- Omega-3 Fatty Acids - Health Professional Fact Sheet
Source consulted: 2026-09-18. This is a reference resource, not a claim that we conducted the studies or tested a product.